Companies › Nuvig Therapeutics
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Hematology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NVG-2089 FcγRIIB agonist (IVIg mimetic) | FCGR2B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy; Immune Thrombocytopenia (ITP) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07027111 | NVG-2089 | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Oct 2026 |
| NCT07095127 | NVG-2089 | Phase 2 | Immune Thrombocytopenia (ITP) | Hematology | Jun 2027 |
Halia Therapeutics Biossil Sundance Biosciences Teikoku Pharma USA Gateway Institute for Brain Research
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.